Andere Sprachen STADA Arzneimittel

Aktien

SAZ

DE0007251803

SAZ

Verzögert Xetra Andere Börsenplätze			% 5 Tage	% 1. Jan.
- ^EUR	-.--%		-1,95 %	-8,87 %

14.03.	Arzneikonzern Stada wächst - Finanzinvestoren prüfen Ausstieg	AW
2023	Alvotech und Stada erhalten Unterstützung des EU-Gremiums für das Biosimilar Stelara	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Xbrane has received additional subscription undertakings corresponding to approximately SEK 18.1 million in the Company's rights issue	04.03.
Alvotech, Stada Get EU Panel Backing for Stelara Biosimilar	10.11.
Calliditas announces filing with UK MHRA for Kinpeygo in IgA nephropathy	03.10.23
STADA and Calliditas announce the filing for full marketing authorization of Kinpeygo® in the EU	28.09.23
Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet	15.08.23
STADA and Xbrane weigh options for ranibizumab biosimilar candidate	25.07.23
Xbrane announce U.S. FDA filing acceptance for a Lucentis® (ranibizumab) biosimilar candidate	21.06.23
STADA AND XBRANE LAUNCH XIMLUCI AS RANIBIZUMAB BIOSIMILAR IN GERMANY	26.05.23
STADA and Xbrane launch Ximluci® as ranibizumab biosimilar in Germany	26.05.23
STADA AND XBRANE SUPPLY XIMLUCI IN ENGLAND UNDER NHS CONTRACT	26.04.23
STADA and Xbrane supply Ximluci® (ranibizumab) in England under NHS contract	25.04.23
STADA and Xbrane launch ranibizumab to support patient access in Europe	03.04.23
European Biosimilar Regulatory Updates	08.02.23
Calliditas Receives Conditional Marketing Authorization from UK MHRA for Kinpeygo in IgA nephropathy	02.02.23
STADA and Xbrane obtain British approval for Ximluci® (ranibizumab) biosimilar referencing Lucentis®	17.01.23
STADA And Xbrane Announce Approval Of Ranibizumab Biosimilar In Europe	15.11.22
Calliditas Therapeutics - Interim Report Q3, 2022 Conditional Marketing Authorization in EU Granted for Kinpeygo	14.11.22
Interim Report Q3, 2022	14.11.22
STADA and Xbrane secure EU approval for Ximluci® (ranibizumab) biosimilar referencing Lucentis®	11.11.22
Calliditas partner STADA launches the first medicine authorized in the EU for treating primary IgA nephropathy	21.09.22

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen STADA Arzneimittel

Aktien

SAZ

DE0007251803

SAZ

Andere Sprachen

Filter